These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10519607)

  • 1. High estradiol levels and high oocyte yield are not detrimental to in vitro fertilization outcome.
    Sharara FI; McClamrock HD
    Fertil Steril; 1999 Sep; 72(3):401-5. PubMed ID: 10519607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum estradiol levels are not detrimental to in vitro fertilization outcome.
    Wu CH; Kuo TC; Wu HH; Yeh GP; Tsai HD
    Taiwan J Obstet Gynecol; 2007 Mar; 46(1):54-9. PubMed ID: 17389191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated E2: oocyte ratio in women undergoing IVF and tubal ET. Correlation with a decrease in the implantation rate.
    Yang JH; Chen HF; Lien YR; Chen SU; Ho HN; Yang YS
    J Reprod Med; 2001 May; 46(5):434-8. PubMed ID: 11396368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of high response of ovary to gonadotropin stimulation on the outcome of in vitro fertilization and embryo transfer or intracytoplasmic sperm injection].
    Lin J; Ye B; Zhao J; Zhou Y; Huang X; Zheng J
    Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):601-3. PubMed ID: 12487934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.
    Schmidt DW; Maier DB; Nulsen JC; Benadiva CA
    Fertil Steril; 2004 Oct; 82(4):841-6. PubMed ID: 15482757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
    Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
    Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of peak and mid-luteal estradiol levels on in vitro fertilization outcome.
    Moraloğlu Ö; Tonguc EA; Özel M; Özakşit G; Var T; Sarikaya E
    Arch Gynecol Obstet; 2012 Mar; 285(3):857-62. PubMed ID: 21938500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify patients from attempting in vitro fertilization.
    Luna M; Grunfeld L; Mukherjee T; Sandler B; Copperman AB
    Fertil Steril; 2007 Apr; 87(4):782-7. PubMed ID: 17207802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taking a basal follicle-stimulating hormone history is essential before initiating in vitro fertilization.
    Roberts JE; Spandorfer S; Fasouliotis SJ; Kashyap S; Rosenwaks Z
    Fertil Steril; 2005 Jan; 83(1):37-41. PubMed ID: 15652884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
    Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
    Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progesterone levels on the day of human chorionic gonadotropin do not predict pregnancy outcome from the transfer of fresh or cryopreserved embryos from the same cohort.
    Moffitt DV; Queenan JT; Shaw R; Muasher SJ
    Fertil Steril; 1997 Feb; 67(2):296-301. PubMed ID: 9022606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure to human chorionic gonadotropin during in vitro maturation does not improve the maturation rate and developmental potential of immature oocytes from patients with polycystic ovary syndrome.
    Ge HS; Huang XF; Zhang W; Zhao JZ; Lin JJ; Zhou W
    Fertil Steril; 2008 Jan; 89(1):98-103. PubMed ID: 17524398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum estradiol levels during controlled ovarian hyperstimulation influence the pregnancy outcome of in vitro fertilization in a concentration-dependent manner.
    Joo BS; Park SH; An BM; Kim KS; Moon SE; Moon HS
    Fertil Steril; 2010 Feb; 93(2):442-6. PubMed ID: 19394001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the oestradiol/oocyte ratio and the outcome of assisted reproductive technology cycles with gonadotropin releasing hormone agonist.
    Var T; Tonguc E; Dogan M; Mollamahmutoglu L
    Gynecol Endocrinol; 2011 Aug; 27(8):558-61. PubMed ID: 20642381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.